Metastatic Breast Cancer Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Breast Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Metastatic Breast Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.

The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report: https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years.
• Metastatic Breast Cancer companies working in the treatment market are RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical, Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical, Kind Pharmaceuticals LLC, Shanghai Miracogen, Dantari, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine, Genor Biopharma, and others, are developing therapies for the Metastatic Breast Cancer treatment
• Emerging Metastatic Breast Cancer therapies in the different phases of clinical trials are- Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, DAN-222, PMD-026, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.
• In July 2024, Mabwell's antibody-drug conjugate (ADC) 9MW2821 received fast-track designation from the US Food and Drug Administration (FDA) for treating triple-negative breast cancer (TNBC).
• In June 2024, G1 Therapeutics reported topline results from the final overall survival (OS) analysis of its Phase III PRESERVE 2 trial, which assessed the efficacy and safety of trilaciclib given before chemotherapy (gemcitabine and carboplatin; GCb) in patients with metastatic triple-negative breast cancer (TNBC).
• In May 2024 The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to inavolisib, an investigational oral treatment, in combination with palbociclib (Ibrance®) and fulvestrant, for adult patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced, or metastatic breast cancer.

Metastatic Breast Cancer Overview
Metastatic breast cancer, also known as stage IV breast cancer, is a form of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, lungs, liver, or brain. It is considered the most advanced stage of the disease. While it is not curable, treatments like targeted therapy, chemotherapy, hormone therapy, and immunotherapy can help control the spread, relieve symptoms, and improve quality of life.

Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:
• Disitamab Vedotin: RemeGen
• EndoTAG®-1 (SB05): SynCore Biotechnology
• trastuzumab duocarmazine: Byondis B.V.
• GNC 035: Sichuan Baili Pharmaceutical Co., Ltd
• Stenoparib (2X-121): Allarity Therapeutics
• HS-10342: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• AND019: Kind Pharmaceuticals LLC
• MRG002: Shanghai Miracogen Inc
• DAN-222: Dantari, Inc.
• PMD-026: Phoenix Molecular Designs
• Patritumab Deruxtecan: Daiichi Sankyo Co., Ltd.
• Tenalisib: Rhizen Pharmaceuticals SA
• OP-1250: Olema Oncology
• Eftilagimod alpha: Immutep S.A.S
• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
• GB491+ Fulvestrant : Genor Biopharma Co., Ltd

Metastatic Breast Cancer Route of Administration
Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Metastatic Breast Cancer Molecule Type
Metastatic Breast Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Metastatic Breast Cancer Pipeline Therapeutics Assessment
• Metastatic Breast Cancer Assessment by Product Type
• Metastatic Breast Cancer By Stage and Product Type
• Metastatic Breast Cancer Assessment by Route of Administration
• Metastatic Breast Cancer By Stage and Route of Administration
• Metastatic Breast Cancer Assessment by Molecule Type
• Metastatic Breast Cancer by Stage and Molecule Type

DelveInsight's Metastatic Breast Cancer Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies
https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Breast Cancer are - RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, and others.

Metastatic Breast Cancer Pipeline Analysis:
The Metastatic Breast Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
• Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies
https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Breast Cancer Pipeline Market Drivers
• Increasing prevalence of breast cancer, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.

Metastatic Breast Cancer Pipeline Market Barriers
• However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.

Scope of Metastatic Breast Cancer Pipeline Drug Insight
• Coverage: Global
• Key Metastatic Breast Cancer Companies: RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical, Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical, Kind Pharmaceuticals LLC, Shanghai Miracogen, Dantari, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine, Genor Biopharma, and others
• Key Metastatic Breast Cancer Therapies: Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, DAN-222, PMD-026, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, and others
• Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
• Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.